GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans
2014/07/29 by Liselotte van Bloemendaal, Richard G. IJzerman, Jennifer S. ten Kulve +6 · 34 citations
Neuroscience · Medicine · #Regulation of Appetite and Obesity #Diet and metabolism studies #Diabetes Treatment and Management
paper · doi:10.2337/db14-0849
Abstract
Gut-derived hormones, such as GLP-1, have been proposed to relay information to the brain to regulate appetite. GLP-1 receptor agonists, currently used for the treatment of type 2 diabetes (T2DM), improve glycemic control and stimulate satiety, leading to decreases in food intake and body weight. We hypothesized that food intake reduction after GLP-1 receptor activation is mediated through appetite- and reward-related brain areas. Obese T2DM patients and normoglycemic obese and lean individuals (n = 48) were studied in a randomized, crossover, placebo-controlled trial. Using functional MRI, we determined the acute effects of intravenous administration of the GLP-1 receptor agonist exenatide, with or without prior GLP-1 receptor blockade using exendin 9-39, on brain responses to food pictures during a somatostatin pancreatic-pituitary clamp. Obese T2DM patients and normoglycemic obese versus lean subjects showed increased brain responses to food pictures in appetite- and reward-related brain regions (insula and amygdala). Exenatide versus placebo decreased food intake and food-related brain responses in T2DM patients and obese subjects (in insula, amygdala, putamen, and orbitofrontal cortex). These effects were largely blocked by prior GLP-1 receptor blockade using exendin 9-39. Our findings provide novel insights into the mechanisms by which GLP-1 regulates food intake and how GLP-1 receptor agonists cause weight loss.
Cited by
- Twelve weeks of exenatide treatment increases [18F]fluorodeoxyglucose uptake by brown adipose tissue without affecting oxidative resting energy expenditure in nondiabetic males
- Glucagon-like peptide 1 agonist and effects on reward behaviour: A systematic review
- From Satiety to Substance Use: Neural Mechanisms of GLP-1 Signaling in Appetite and Reward
- Do GLP-1 Receptor Agonists Alter Brain Responses to Reward-Related Cues? A Systematic Review
- Treatment of Hypothalamic Obesity With GLP-1 Analogs
- Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report
- GLP-1 and Its Analogs: Does Sex Matter?
- The (dys)regulation of energy storage in obesity
- Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis
- Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. [europepmc]
- GLP-1 based therapeutics: simultaneously combating T2DM and obesity. [europepmc]
- Regulation of energy balance by a gut-brain axis and involvement of the gut microbiota. [europepmc]
- Sex and estrogens alter the action of glucagon-like peptide-1 on reward. [europepmc]
- GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial. [europepmc]
- Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial. [europepmc]
- Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: A randomized, placebo-controlled, crossover study. [europepmc]
- Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review. [europepmc]
- Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. [europepmc]
- Homeostatic and non-homeostatic controls of feeding behavior: Distinct vs. common neural systems. [europepmc]
- Food addiction: a valid concept? [europepmc]
- Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function. [europepmc]
- Direct and indirect effects of liraglutide on hypothalamic POMC and NPY/AgRP neurons - Implications for energy balance and glucose control. [europepmc]
- Glucagon-like peptide 1 (GLP-1). [europepmc]
- Semaglutide lowers body weight in rodents via distributed neural pathways. [europepmc]
- GDF15 Induces an Aversive Visceral Malaise State that Drives Anorexia and Weight Loss. [europepmc]
- Health Benefits of Lactic Acid Bacteria (LAB) Fermentates. [europepmc]
- A Role for GLP-1 in Treating Hyperphagia and Obesity. [europepmc]
- GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. [europepmc]
- Can GLP-1 Be a Target for Reward System Related Disorders? A Qualitative Synthesis and Systematic Review Analysis of Studies on Palatable Food, Drugs of Abuse, and Alcohol. [europepmc]
- Glucagon-like peptide-1 (GLP-1) signalling in the brain: From neural circuits and metabolism to therapeutics. [europepmc]
- GLP-1 physiology informs the pharmacotherapy of obesity. [europepmc]
- The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials. [europepmc]
- An overview of fermentation in the food industry - looking back from a new perspective. [europepmc]
- Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. [europepmc]
Related